Mounjaro Outperforms Ozempic in Weight Loss, Real-World Study Shows

Patients on Mounjaro were more than three times as likely to lose at least 15% of their body weight compared to those on Ozempic, with further trials underway.

Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's Ozempic, according to an analysis of health records and other data.
Within one year of starting treatment, 42.3% of those taking Mounjaro had lost at least 15% of their weight, compared with 19.3% among patients taking Ozempic.
Patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking Ozempic.
After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight.
A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes. Those results are not expected until 2025.